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THE CFRD GUIDELINES COMMITTEE
C
ystic ﬁbrosis–related diabetes
(CFRD) is the most common co-
morbidity in people with cystic ﬁ-
brosis (CF), occurring in 20% of
adolescents and 40–50% of adults (1).
Whileitsharesfeaturesoftype1andtype
2 diabetes, CFRD is a distinct clinical en-
tity. It is primarily caused by insulin in-
sufﬁciency, although ﬂuctuating levels of
insulin resistance related to acute and
chronic illness also play a role. The addi-
tional diagnosis of CFRD has a negative
impact on pulmonary function and sur-
vival in CF, and this risk disproportion-
ately affects women (2–4). In contrast to
patients with other types of diabetes,
there are no documented cases of death
from atherosclerotic vascular disease in
patients with CFRD, despite the fact that
somenowliveintotheirsixthandseventh
decades.
These guidelines are the result of a
joint effort between the Cystic Fibrosis
Foundation (CFF), the American Diabe-
tes Association (ADA), and the Pediatric
Endocrine Society (PES). They are in-
tended for use by CF patients, their care
partners, and health care professionals
andincluderecommendationsforscreen-
ing, diagnosis, and medical management
ofCFRD.Thisreportfocusesonaspectsof
care unique to CFRD. A comprehensive
summaryofrecommendationsforallpeo-
plewithdiabetescanbefoundintheADA
Standards of Medical Care, published
annually in the January supplement to
Diabetes Care (5).
METHODS— In2009,CFFincollab-
oration with ADA and PES convened a
committee of CF and diabetes experts to
update clinical care guidelines for CFRD.
InvestigatorsatJohnsHopkinsUniversity
conducted evidence reviews on relevant
clinical questions identiﬁed by the guide-
lines committee. The reviews were pro-
vided to the committee to use in
developing recommendations. Where
possible, the evidence for each recom-
mendationwasconsideredandgradedby
the committee using the ADA (5) and the
U.S.PreventiveServicesTaskForce(USP-
STF) (6) grading systems (Table 1). Rec-
ommendations from existing published
guidelines were used when available and
appropriate, and these are indicated as
consensus statements. The committee
also made consensus recommendations
for topics not included in the evidence
reviewsorforwhichlimitedevidencewas
available in the literature. Recommenda-
tionswillbeupdatedaswarrantedbynew
evidence, and the guidelines will be re-
viewed 3 years after release date to deter-
mine if an update is needed. A summary
of the committee’s recommendations is
presented in Table 2.
SCREENING— CFRD is often clini-
cally silent. In other populations, the pri-
mary consequences of unrecognized
diabetesaremacrovascularandmicrovas-
cular disease. In CF, the nutritional and
pulmonary consequences of diabetes are
of greater concern. CFRD is associated
withweightloss,proteincatabolism,lung
function decline, and increased mortality
(2,3,7–17), and thus regular screening is
warranted.
Screening tests for CFRD
Although hemoglobin A1C (A1C) may
become the standard screening test for
type 2 diabetes (5), the committee con-
cluded that it is not sufﬁciently sensitive
for diagnosis of CFRD and thus should
notbeusedasascreeningtest.Eightstud-
ies were identiﬁed that assessed A1C as a
screening test in this population (7,18–
24). The authors of one prospective co-
hort study of 62 participants with CF and
107healthycontrolsubjectsreportedthat
A1C levels were higher in the CF group
than among the control subjects, leading
them to suggest that the use of A1C was
appropriate (18). However, six studies
(including two prospective cohort stud-
ies [7,21], two cross-sectional studies
[19,20], one case-control study [23], and
one case series [22[) with a total of 477
participants demonstrated low degrees of
correlation between A1C and glucose tol-
erance status (7,19–23). Additionally, a
cross-sectional study of 191 participants
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dictive value of the A1C test (24).
Use of A1C as a screening test for
CFRD is not recommended. (ADA-B;
USPSTF-D)
Fructosamine,urineglucose,andrandom
glucose levels have low sensitivity in the
CF population (20,23,25). Continuous
glucose monitoring is not recommended
as a screening tool because intermittent
hyperglycemia detected in this fashion is
not diagnostic for diabetes and there are
no outcome data to determine its clinical
signiﬁcance. Fasting plasma glucose
(FPG) identiﬁes patients with CFRD with
but not those without fasting hyperglyce-
mia (FH), and thus this test will miss the
diagnosis of diabetes in approximately
half of CF patients (1). Self-monitoring of
blood glucose (SMBG) with home meters
is also not sufﬁciently accurate to screen
for CFRD given that the International Or-
ganization for Standardization only re-
quires that 95% of readings be within
20% of the actual glucose level (26).
Because of the poor performance of
A1C and other tests, the oral glucose tol-
erancetest(OGTT)isthescreeningtestof
choice for CFRD. Although it is an imper-
fect test due to the inherent variability of
the test and the variability observed in indi-
vidual CF patients over time, longitudinal
studies demonstrate that a diabetes diagno-
sis by OGTT correlates with clinically im-
portant CF outcomes including the rate of
lung function decline over the next 4 years
(12), the risk of microvascular complica-
tions (27), and the risk of early death (1,2).
In a multicenter, multinational study, the
OGTT identiﬁed patients who beneﬁted
from insulin therapy (28).
The OGTT should be performed in
the morning during a period of stable
baseline health (at least 6 weeks since an
acute exacerbation) using the World
Health Organization protocol (5). Pa-
tients fast for at least 8 h (water is permit-
ted) and should consume a minimum of
150 g (600 kcal) of carbohydrate per day
for the preceding 3 days (generally not an
issue because CF patients have high-
calorie diets). The patient drinks a stan-
dard beverage containing 1.75 g/kg
glucose(maximum75g)dissolvedinwa-
ter and sits or lies quietly for 2 h. Glucose
levels are measured at baseline and 2 h.
Unless the patient is experiencing classi-
cal symptoms of polyuria and polydipsia
in the presence of a glucose level 200
mg/dl (11.1 mmol/l) or has two more di-
agnosticcriteriafordiabetes(suchasboth
fasting and 2-h glucose elevation or a di-
abetes pattern on OGTT in the presence
of an A1C level 6.5%), the test should
be conﬁrmed by repeat testing.
Screening for CFRD should be
performed using the 2-h 75-g OGTT.
(ADA-E; Consensus)
The age of screening for CFRD
Three studies with a total of 811 partici-
pants were identiﬁed that provided infor-
mation about the appropriate age at which
to start screening for CFRD (1,21,24).
Thesestudies—aretrospectivecohortstudy
(1), a prospective cohort study (21), and a
cross-sectional study (24)—reported a sig-
niﬁcantly higher prevalence and incidence
of CFRD beyond the ﬁrst decade of life.
Screening included both pancreatic sufﬁ-
Table 1—Evidence-grading system for clinical practice recommendations
ADA classiﬁcation system
Level of
evidence Description
A Clear evidence from well-conducted, generalizable, randomized, controlled trials that are adequately powered, including
● Evidence from a well-conducted multicenter trial
● Evidence from a meta-analysis that incorporated quality ratings in the analysis
Compelling nonexperimental evidence, i.e., “all-or-none” rule developed by the Centre for Evidence-Based Medicine at Oxford
Supportive evidence from well-conducted, randomized, controlled trials that are adequately powered, including
● Evidence from a well-conducted trial at one or more institutions
● Evidence from a meta-analysis that incorporated quality ratings in the analysis
B Supportive evidence from well-conducted cohort studies, including
● Evidence from a well-conducted prospective cohort study or registry
● Evidence from a well-conducted meta-analysis of cohort studies
Supportive evidence from a well-conducted case-control study
C Supportive evidence from poorly controlled or uncontrolled studies, including
● Evidence from randomized clinical trials with one or more major or three or more minor methodological ﬂaws that could
invalidate the results
● Evidence from observational studies with high potential for bias (such as case series with comparison with historical controls)
Conﬂicting evidence with the weight of evidence supporting the recommendation
E Expert consensus or clinical experience
USPSTF recommendation classiﬁcation system
Estimate of effect
Quality of evidence Substantial Moderate Small Zero/negative*
High A B C D
Moderate B B C D
Low Insufﬁcient (I)
*A study with signiﬁcant ﬁndings against something is given a grade of D.
Clinical care of CFRD
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Screening recommendations
1. The use of A1C as a screening test for CFRD is not recommended. (ADA-B; USPSTF-D)
2. Screening for CFRD should be performed using a 2-h 75-g OGTT. (ADA-E; Consensus)
3. Annual screening for CFRD should begin by age 10 years in all CF patient s who do not have CFRD. (ADA B; USPSTF-B)
4. CF patients with acute pulmonary exacerbation requiring intravenous antibiotics and/or systemic glucocorticoids should be screened for
CFRD by monitoring fasting and 2-h postprandial plasma glucose levels for the ﬁrst 48 h. If elevated blood glucose levels are found by
SMBG, the results must be conﬁrmed by a certiﬁed laboratory. (ADA-E; Consensus)
5. Screening for CFRD by measuring mid- and immediate postfeeding plasma glucose levels is recommended for CF patients on
continuous enteral feedings, at the time of gastrostomy feeding initiation and then monthly by SMBG. Elevated glucose levels detected
by SMBG must be conﬁrmed by a certiﬁed laboratory. (ADA-E; Consensus)
6. Women with CF who are planning a pregnancy or conﬁrmed pregnant should be screened for preexisting CFRD with a 2-h 75-g fasting
OGTT if they have not had a normal CFRD screen in the last 6 months. (ADA-E; Consensus)
7. Screening for gestational diabetes mellitus is recommended at both 12–16 weeks’ and 24–28 weeks’ gestation in pregnant women with
CF not known to have CFRD, using a 2-h 75-g OGTT with blood glucose measures at 0, 1, and 2 h. (ADA-E; Consensus)
8. Screening for CFRD using a 2-h 75-g fasting OGTT is recommended 6–12 weeks after the end of the pregnancy in women with
gestational diabetes mellitus (diabetes ﬁrst diagnosed during pregnancy). (ADA-E; Consensus)
9. CF patients not known to have diabetes who are undergoing any transplantation procedure should be screened preoperatively by OGTT
if they have not had CFRD screening in the last 6 months. Plasma glucose levels should be monitored closely in the perioperative
critical care period and until hospital discharge. Screening guidelines for patients who do not meet diagnostic criteria for CFRD at the
time of hospital discharge are the same as for other CF patients. (ADA-E; Consensus)
Diagnosis recommendations
1. During a period of stable baseline health the diagnosis of CFRD can be made in CF patients according to standard ADA criteria. Testing
should be done on 2 separate days to rule out laboratory error unless there are unequivocal symptoms of hyperglycemia (polyuria and
polydipsia); a positive FPG or A1C can be used as a conﬁrmatory test, but if it is normal the OGTT should be performed or repeated. If
the diagnosis of diabetes is not conﬁrmed, the patient resumes routine annual testing. (ADA-E; Consensus)
● 2-h OGTT plasma glucose 200 mg/dl (11.1 mmol/l)
● FPG 126 mg/dl (7.0 mmol/l)
● A1C  6.5% (A1C 6.5% does not rule out CFRD because this value is often spuriously low in CF.)
● Classical symptoms of diabetes (polyuria and polydipsia) in the presence of a casual glucose level 200 mg/dl (11.1 mmol/l)
2. The diagnosis of CFRD can be made in CF patients with acute illness (intravenous antibiotics in the hospital or at home, systemic
glucocorticoid therapy) when FPG levels 126 mg/dl (7.0 mmol/l) or 2-h postprandial plasma glucose levels 200 mg/dl (11.1 mmol/
l) persist for more than 48 h. (ADA-E; Consensus)
3. The diagnosis of CFRD can be made in CF patients on enteral continuous drip feedings when mid- or postfeeding plasma glucose levels
exceed 200 mg/dl (11.1 mmol/l) on 2 separate days. (ADA-E; Consensus)
4. Diagnosis of gestational diabetes mellitus should be made based on the recommendations of the IADPSG (45) where diabetes is
diagnosed based on 0-, 1-, and 2-h glucose levels with a 75-g OGTT if any one of the following is present:
● FPG 92 mg/dl (5.1 mmol/l)
● 1-h plasma glucose 180 mg/dl (10.0 mmol/l)
● 2-h plasma glucose 153 mg/dl (8.5 mmol/l) (ADA-E; Consensus)
CF patients with gestational diabetes mellitus are not considered to have CFRD, but require CFRD screening 6–12 weeks after the end
of the pregnancy. (ADA-E; Consensus)
5. Distinguishing between CFRD with and without FH is not necessary. (ADA-B, USPSTF-D)
6. The onset of CFRD should be deﬁned as the date a person with CF ﬁrst meets diagnostic criteria, even if hyperglycemia subsequently
abates. (ADA-E; Consensus)
Management recommendations
1. Patients with CFRD should ideally be seen quarterly by a specialized multidisciplinary team with expertise in diabetes and CF. (ADA-E;
Consensus)
2. Patients with CFRD should receive ongoing diabetes self-management education from diabetes education programs that meet national
standards for DSME. (ADA-E; Consensus)
3. Patients with CFRD should be treated with insulin therapy. (ADA-A; USPSTF-B)
4. Oral diabetes agents are not as effective as insulin in improving nutritional and metabolic outcomes in CFRD and are not recommended
outside the context of clinical research trials. (ADA-A; USPSTF-D)
5. Patients with CFRD who are on insulin should perform SMBG at least three times a day. (ADA-E; Consensus)
6. Patients with CFRD should strive to attain plasma glucose goals as per the ADA recommendations for all people with diabetes, bearing
in mind that higher or lower goals may be indicated for some patients and that individualization is important. (ADA-E; Consensus)
7. A1C measurement is recommended quarterly for patients with CFRD. (ADA-E; Consensus)
8. For many patients with CFRD, A1C treatment goal is 7%, bearing in mind that higher or lower goals may be indicated for some
patients and that individualization is important. (ADA-B; USPSTF-B)
9. CFF evidence-based guidelines for nutritional management are recommended for patients with CFRD. (ADA-E; Consensus)
10. Patients with CFRD should be advised to do moderate aerobic exercise for at least 150 min per week. (ADA-E; Consensus)
(continued on following page)
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tee concluded that these ﬁndings suggest
thatannualscreeningforCFRDshouldstart
by age 10 years in all CF patients. Because
clinicaldeteriorationinnutritionalandpul-
monarystatusbegins6–24monthspriorto
a diagnosis of CFRD (29,30), early detec-
tion by annual screening is warranted.
Annual screening for CFRD should
begin by age 10 years in all CF
patients who do not have CFRD.
(ADA-B; USPSTF-B)
Screening of CF patients during
acute illness
CF patients experience frequent pulmo-
nary exacerbations, some of which
require treatment either in the hospital or
at home with intravenous antibiotics.
Treatment at times includes systemic glu-
cocorticoids. In clinical experience, hyper-
glycemia that develops during acute illness
occasionally resolves after a day or two of
medicaltherapy,butusuallylastsforatleast
2–6 weeks. CF patients are frequently ill,
and hyperglycemia returns with each sub-
sequentboutofillness,oftenseveraltimesa
year. Insulin deﬁciency and insulin resis-
tance generally progress over time. Long-
term microvascular (27) and pulmonary
(1,2) outcomes correlate with duration of
CFRD ﬁrst diagnosed during acute illness,
even with intervening periods of normal or
impaired glucose tolerance (IGT).
During acute illness and/or a pulse of
systemic glucocorticoid therapy, glucose
levels should be monitored for at least the
ﬁrst 48 h, preferably fasting and 2 h post-
prandially. If glucose levels do not meet
diagnostic criteria for CFRD, testing can
be discontinued after 48 h. For patients
receiving therapy at home, SMBG can be
performed.However,SMBGlevelsarenot
sufﬁciently accurate to make a diagnosis
of CFRD, and hyperglycemia should be
conﬁrmed by laboratory plasma glucose
measurement.
CF patients with acute pulmonary
exacerbation requiring intravenous
antibiotics and/or systemic
glucocorticoids should be screened for
CFRD by monitoring fasting and 2-h
postprandial plasma glucose levels for
the ﬁrst 48 h. If elevated blood glucose
levels are found by SMBG, the results
must be conﬁrmed by a certiﬁed
laboratory. (ADA-E; Consensus)
Screening of CF patients during
continuous drip enteral feedings
Supplemental continuous drip feedings are
commonlyprescribedformalnourishedCF
patients. Although there are few data avail-
able speciﬁc to this situation, mid-feeding
hyperglycemia may compromise efforts to
gain weight. The Committee felt that glu-
cose levels in the middle and immediately
after the gastrostomy tube feeding should
be measured in the hospital and at these
same time points once a month at home
using SMBG. SMBG levels are not sufﬁ-
ciently accurate to make a diagnosis of
CFRD, and hyperglycemia detected by
SMBG should be conﬁrmed by laboratory
plasma glucose measurement.
Screening for CFRD by measuring
mid- and immediate postfeeding
plasma glucose levels is recommended
for CF patients on continuous enteral
feedings, at the time of gastrostomy
tube feeding initiation and then
monthly at home. Elevated glucose
levels detected by SMBG must be
conﬁrmed by a certiﬁed laboratory.
(ADA-E; Consensus)
Screening CF patients who are
pregnant or planning a pregnancy
Pregnancy is a state of marked insulin re-
sistance, and many women with CF can-
not produce the extra insulin required to
meet this demand (31–33). In addition to
the usual concerns about the effect of hy-
perglycemia on the fetus, diabetes can ex-
acerbate the difﬁculties many women
with CF have in achieving a positive pro-
tein balance and sufﬁcient weight gain
during pregnancy (32).
Women with CF not known to have
CFRD who are contemplating pregnancy
should be evaluated prior to conception
to rule out preexisting CFRD or be tested
immediately upon conﬁrmation of the
pregnancy if they have not had an OGTT
intheprevious6months.Becausewomen
with CF are at high risk for development
of hyperglycemia during pregnancy (ges-
tational diabetes mellitus), the 2-h 75-g
OGTT should be performed at the end of
both the ﬁrst and second trimesters.
Women with CF who are planning a
pregnancy or conﬁrmed pregnant
should be screened for preexisting
CFRD with a 2-h 75-g fasting OGTT
if they have not had a normal CFRD
screen in the last 6 months. (ADA-E;
Consensus)
Screening for gestational diabetes
mellitus is recommended at both
12–16 weeks’ and 24–28 weeks’
gestation in pregnant women with
CF not known to have CFRD, using
a 2-h 75-g OGTT with blood glucose
measures at 0, 1, and 2 h. (ADA-E;
Consensus)
Screening for CFRD using a 2-h 75-g
fasting OGTT is recommended 6–12
weeks after the end of the pregnancy
in women with gestational diabetes
mellitus (diabetes ﬁrst diagnosed
during pregnancy). (ADA-E;
Consensus)
Table 2—Continued
Diabetes complications recommendations
1. Education about the symptoms, prevention, and treatment of hypoglycemia, including the use of glucagon, is recommended for
patients with CFRD and their care partners. (ADA-E; Consensus)
2. Patients with CFRD should have their blood pressure measured at every routine diabetes visit as per ADA guidelines. Patients found to
have systolic blood pressure 130 mmHg or diastolic blood pressure 80 mmHg or 90th percentile for age and sex for pediatric
patients should have repeat measurement on a separate day to conﬁrm a diagnosis of hypertension. (ADA-E; Consensus)
3. Annual monitoring for microvascular complications of diabetes is recommended using ADA guidelines, beginning 5 years after the
diagnosis of CFRD or, if the exact time of diagnosis is not known, at the time that FH is ﬁrst diagnosed. (ADA-E; Consensus)
4. Patients with CFRD diagnosed with hypertension or microvascular complications should receive treatment as recommended by ADA for
all people with diabetes, except that there is no restriction of sodium and, in general, no protein restriction. (ADA-E; Consensus)
5. An annual lipid proﬁle is recommended for patients with CFRD and pancreatic exocrine sufﬁciency or if any of the following risk
factors are present: obesity, family history of coronary artery disease, or immunosuppressive therapy following transplantation. (ADA-E;
Consensus)
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transplantation
There is an almost universal require-
ment for insulin in the immediate criti-
cal care postoperative period in CF
patients undergoing transplantation
procedures, and many have long-term
insulin requirements after transplanta-
tion (34–36). A diagnosis of CFRD
prior to transplantation may increase
complications of surgery and has a neg-
ative impact on survival, at least in the
early postoperative period when infec-
tion, bleeding, and multiorgan failure
are the most common causes of death
(34,37). Aggressive management may
have a positive impact on outcomes
(35).
CF patients not known to have dia-
betes who are undergoing any trans-
plantation procedure should be
screened preoperatively by OGTT if
theyhavenothadCFRDscreeningin
the last 6 months. Plasma glucose
levels should be monitored closely
in the perioperative critical care pe-
riod and until hospital discharge.
Screening guidelines for patients
who do not meet diagnostic criteria
for CFRD at the time of hospital dis-
charge are the same as for other CF
patients. (ADA-E; Consensus)
DIAGNOSIS (Fig. 1)
The spectrum of glucose tolerance
abnormalities in CF
Diabetes is part of a continuum of glucose
tolerance abnormalities deﬁned by ADA
(supplementary Table 1, available at http://
care.diabetesjournals.org/cgi/content/full/
dc10-1768/DC1). Few CF patients have
truly “normal” glucose tolerance. Many pa-
tients with normal fasting and 2-h glucose
levels have elevation in the middle of the
OGTT (indeterminate glycemia [INDET])
or when assessed randomly or by continu-
ous glucose monitoring. Impaired fasting
glucose (IFG) (100–125 mg/dl [5.6–6.9
mmol/l[) may also be present (20,38). The
clinical signiﬁcance of IFG or INDET in CF
is not known. In the general population,
they are considered pre-diabetic condi-
tions, associated with a high risk of future
development of diabetes (39). In prepuber-
tal children with CF both IGT and INDET
are associated with early-onset CFRD (40).
Criteria for the diagnosis of CFRD in
stable outpatients
ADA has established diagnostic criteria
for diabetes that include speciﬁc fasting
glucose levels, 2-h OGTT glucose levels
(5),andA1Clevels.Theyarebasedonthe
population risk of microvascular disease,
and patients with CF are also at risk for
these complications (27,41–43). The
committee questioned whether the diag-
nostic thresholds should be lower for the
CF population as CFRD is known to have
anegativeimpactonCFpulmonarystatus
(2,10,11), given that pulmonary disease
is the chief morbidity in CFRD. Even less
severe glucose tolerance abnormalities
suchasIGTareassociatedwithlungfunc-
tion decline (12,17). However, sufﬁcient
outcome-based data are not available at
present to determine whether more strin-
gent diagnostic glucose thresholds more
appropriately reﬂect risk for the CF
population.
During a period of stable baseline
health, the diagnosis of CFRD can be
Figure 1—Criteria for the diagnosis of CFRD under different conditions.
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dard ADA criteria. Testing should be
done on two separate days to rule out
laboratory error unless there are un-
equivocal symptoms of hyperglycemia
(polyuria and polydipsia); a positive
FPG or A1C can be used as a conﬁrma-
tory test, but if it is normal the OGTT
should be performed or repeated. If the
diagnosis of diabetes is not conﬁrmed,
the patient resumes routine annual test-
ing. (ADA-E; Consensus)
● 2-h OGTT plasma glucose 200 mg/dl
(11.1 mmol/l)
● FPG 126 mg/dl (7.0 mmol/l)
● A1C6.5%(A1C6.5%doesnotrule
out CFRD because this value is often
spuriously low in CF.)
● Classical symptoms of diabetes (poly-
uriaandpolydipsia)inthepresenceofa
casual glucose level 200 mg/dl (11.1
mmol/l)
Diagnosing CFRD during acute
illness or continuous feedings
There are special situations when a diag-
nosis of CFRD must be considered in pa-
tientswhoarenotintheirbaselinestateof
health. CF patients frequently ﬁrst de-
velop hyperglycemia during stressors
suchasacuteillnessorcontinuousenteral
nutrition. Blood glucose levels may nor-
malize when the stress is not present. In
the past, this was called “intermittent
CFRD” (44). Longitudinal outcome data
have shown that CF morbidity and mor-
tality are associated with CFRD ﬁrst diag-
nosed in the acute illness setting when
hyperglycemia has persisted beyond 48 h
(1,2,27). Based on this experience, the
committee developed the following
recommendations.
The diagnosis of CFRD can be made
in CF patients with acute illness
(intravenous antibiotics in the
hospital or at home, systemic
glucocorticoid therapy) when FPG
levels >126 mg/dl (7.0 mmol/l) or
2-h postprandial plasma glucose
levels >200 mg/dl (11.1 mmol/l)
persist for more than 48 h. (ADA-E;
Consensus)
The diagnosis of CFRD can be made in
CF patients on enteral continuous drip
feedings when mid- or postfeeding
plasma glucose levels exceed 200 mg/dl
(11.1 mmol/l) on two separate days.
(ADA-E; Consensus)
Gestational diabetes mellitus in CF
In the general population, the Hypergly-
cemia and Adverse Pregnancy Outcome
(HAPO) study showed a continuous risk
of adverse perinatal and maternal out-
comes with increasing glycemia at 24–28
weeks’ gestation (45), and a recent multi-
center, randomized study has demon-
strated that aggressive treatment of mild
gestational diabetes mellitus improves
outcomes (46).
Diagnosis of gestational diabetes
mellitus should be made based on
the recommendations of the
International Association of the
Diabetes and Pregnancy Study
Groups (IADPSG) (45) where
diabetes is diagnosed based on 0-,
1-, and 2-h glucose levels with a 75-g
OGTT if any one of the following is
present:
● FPG >92 mg/dl (5.1 mmol/l)
● 1-h plasma glucose >180 mg/dl
(10.0 mmol/l)
● 2-h plasma glucose >153 mg/dl
(8.5 mmol/l)
CF patients with gestational
diabetes mellitus are not considered
to have CFRD but require CFRD
screening 6–12 weeks after the end
of the pregnancy. (ADA-E;
Consensus)
Differentiating CFRD with and with-
out FH
The 1998 CFF CFRD Consensus Con-
ference recommended that CFRD pa-
tients with and without FH (FH and
FH-, respectively) be categorized sepa-
rately because differences in their treat-
ment needs were unknown (44).
However, in a recent retrospective co-
hort study, 78 patients with CFRD FH-
and 77 with CFRD FH were treated
with insulin with similar positive effects
on nutritional status and lung function
(1). In addition, in a randomized con-
trolled trial, insulin therapy reversed
chronic weight loss in patients with
CFRD FH- (28), suggesting that both
groups of CFRD patients should receive
insulin treatment and that there is no
need to distinguish them diagnosti-
cally.
Distinguishing between CFRD with
and without FH is not necessary.
(ADA-B; USPSTF-D)
Date of onset of CFRD
Deﬁning the date of onset of CFRD is
important because long-term outcomes
are related to disease duration. Glucose
tolerance gradually worsens with age in
CF as a result of steadily declining insu-
lin production (1,47). At any point in
time, however, an individual’s glucose
tolerancemayacutelyﬂuctuatedepend-
ing on his or her general state of health.
The committee deﬁned the onset of
CFRD as the ﬁrst time a patient meets
diabetes diagnostic criteria. Longitudi-
nal studies of patients whose date of di-
agnosis was considered to be either the
ﬁrst time they had a positive OGTT or
the ﬁrst time they had persistent hyper-
glycemia during acute illness have
shown that duration of CFRD deter-
mined by these criteria correlates with
clinically relevant outcomes including
microvascular complications (27) and
mortality (1,2). Hyperglycemia may re-
solve without treatment during periods
of stable health, but insulin secretion
remains insufﬁcient to control glucose
under stress, and hyperglycemia will
recur.
Although in the general population
critically ill patients who experience
stress hyperglycemia are not given a di-
agnosis of diabetes, our recommenda-
tion differs for CF patients who develop
hyperglycemia during acute exacerba-
tions of their chronic illness. In CF, ill-
ness-associated hyperglycemia is a
reﬂectionofinsulininsufﬁciencyaswell
as resistance and is a recurrent event.
Deﬁningthediseasebythiscriterionen-
courages early intervention to improve
long-term outcomes.
The onset of CFRD should be
deﬁned as the date a person with CF
ﬁrst meets diagnostic criteria, even if
hyperglycemia subsequently abates.
(ADA-E; Consensus)
MANAGEMENT OF CFRD
The care team
As per ADA guidelines, CFRD should be
managed by a multidisciplinary team of
health professionals with expertise in CF
and diabetes (5). The diabetes team
should be intimately familiar with CFRD,
recognizing differences between this and
type 1 and type 2 diabetes pathophysiol-
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betweendiabetesandCFcareprovidersis
essential. Poor team communication and
inadequate or conﬂicting information
from health care providers have been
identiﬁed as signiﬁcant sources of stress
for patients with CFRD (48).
Although there are few CF-speciﬁc
data, it has been well established in the
general diabetes population that patients
must be given the educational tools and
supporttheyneedtoassumeacentralrole
in determining their treatment goals and
implementing the management plan (5).
Initial and ongoing diabetes self-
management education (DSME) is an in-
tegral component of care. In addition to
medical issues, the role of the patient-
centered medical team is to encourage
and support the patient and family. The
treatment team should address psychoso-
cial issues and recognize the risk of de-
pression. Emotional well-being is
strongly correlated with diabetes out-
comes, and the additional diagnosis of di-
abetes can be a signiﬁcant burden. There
may also be ﬁnancial concerns associated
with this diagnosis.
Patients with CFRD should ideally
be seen quarterly by a specialized
multidisciplinary team with
expertise in diabetes and CF.
(ADA-E; Consensus)
Patients with CFRD should receive
ongoing DSME from diabetes
education programs that meet
national standards for DSME. (ADA-
E; Consensus)
Medical therapy
Patients with CFRD are insulin insufﬁ-
cient, and based on available data, insulin
is the only recommended treatment.
There is evidence that CF patients on in-
sulin therapy who achieve glycemic con-
trol demonstrate improvement in weight,
protein anabolism, pulmonary function,
and survival. Ten studies (with a total of
783 participants) were identiﬁed that ad-
dressed insulin therapy in CFRD, includ-
ing one randomized controlled trial (28),
ﬁve before-after studies (49–53), one ret-
rospective cohort study (1), one prospec-
tive cohort study (54), and two case-
control studies (29,30). These studies
reported improved outcomes associated
with the use of insulin in patients with
CFRD, including those without FH. Re-
portedoutcomesincludedimprovedlung
function (ﬁve studies) (29,30,49,51,54),
improved nutritional status (seven stud-
ies),(28,29,49–53),improvedbloodglu-
cose/A1C control (two studies) (50,53),
decreased pulmonary exacerbation rates
(one study) (49), and decreased mortality
(one study) (1).
There is little evidence regarding
the superiority of speciﬁc insulin regi-
mens in CFRD, and clinical judgment
should be used to choose the best regi-
men for each patient. CFRD FH is
usually treated with standard basal-
bolus insulin regimens, including a
combination of basal and rapid-acting
insulin by multiple daily subcutaneous
injections, or rapid-acting insulin by
continuous subcutaneous infusion (in-
sulin pump) (1,50,54,55). CFRD pa-
tients still have endogenous insulin
secretion, and, except during acute ill-
ness,treatmentisoftensimilartothatof
patientswithtype1diabetesinthehon-
eymoon period. During acute illness or
systemic glucocorticoid treatment, in-
sulin requirements steeply rise, two- to
fourfold. Once the illness resolves, it
generally takes about 4–6 weeks for in-
sulin requirements to gradually return
to baseline. Careful monitoring for hy-
poglycemia is required during this
period. Speciﬁc insulin treatment sug-
gestions are presented in supplemen-
tary Table 2.
At the time of the last consensus con-
ference (44), it was not clear whether
CFRDpatientswithoutFHshouldreceive
insulin treatment. A recently completed
trial demonstrated that treatment with
premeal rapid-acting insulin was able to
reverse chronic weight loss in this popu-
lation, and thus insulin therapy is indi-
cated (28). Whether basal insulin therapy
alone (54) or basal-bolus insulin therapy
would be as beneﬁcial as premeal insulin
alone in CFRD FH- remains to be
determined.
The available data suggest that oral
agents are not as effective as insulin in
CFRD. Four studies (with a total of 153
participants) compared oral hypoglyce-
mictherapywithinsulintherapyinCFRD
(14,28,56,57). These included one ran-
domized controlled trial (28), one ran-
domized controlled crossover trial (57),
one prospective cohort study (56), and
one retrospective cohort study (14). Oral
hypoglycemic agents studied included
sulfonylureas (e.g., glyburide), met-
formin, meglitinides (e.g., repaglinide),
and thiazolidinediones. The two observa-
tional studies (14,56) reported no differ-
ences in lung function, nutritional status,
or blood glucose/A1C control comparing
those who received oral hypoglycemic
agents with those who received insulin.
However, two randomized studies sug-
gestedthatoralhypoglycemicagentswere
not as effective as insulin in improving
nutritional status (28), blood glucose/
A1Ccontrol(28),and2-hand5-hinsulin
area under the curve (57). Potential CF-
speciﬁc concerns associated with various
noninsulin diabetes agents are presented
in supplementary Table 3.
CF patients with CFRD should be
treated with insulin therapy.
(ADA-A; USPSTF-B)
Oral diabetes agents are not as
effective as insulin in improving
nutritional and metabolic outcomes
in CFRD and are not recommended
outside the context of clinical
research trials. (ADA-A; USPSTF-D)
Management goals
ADAhasestablishedplasmaglucosegoals
for people with diabetes (5). These are
primarily based on the need to decrease
the risk of microvascular complications
and thus apply to CFRD with slight mod-
iﬁcations (supplementary Table 4).
Whether more stringent goals should be
adopted for CF patients based on the re-
lationship between hyperglycemia, nutri-
tion, and pulmonary disease cannot be
determined at present.
To safely achieve glucose goals, ADA
recommends that all patients on insulin
therapy perform SMBG at least three
times daily (5). Continuous glucose mon-
itoring has been validated in CF and may
beusefulforclinicalmanagementinsome
patients (58–60).
Patients with CFRD who are on
insulin should perform SMBG at
least three times a day. (ADA-E;
Consensus)
Patients with CFRD should strive
to attain plasma glucose goals as
per the ADA recommendations for
all people with diabetes, bearing in
mind that higher or lower goals
may be indicated for some patients
and that individualization is
important. (ADA-E; Consensus)
ADAconsidersA1Ctheprimarytar-
get for glycemic control in type 1 and
type2diabetes(5).AlthoughA1Clevels
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(7,20,21,23,27,59,61), they are gener-
ally higher in CF patients with CFRD
compared with those with normal glu-
cose tolerance or IGT, and elevated lev-
els are associated with increased risk of
microvascular complications (27). In
onestudyofpatientswith10-yeardu-
ration CFRD, those with retinopathy
and/or microalbuminuria had average
A1Clevelsof8.0%comparedwith5.8%
in CFRD patients with no eye or kidney
changes, and 83% of those with micro-
vascular complications had A1C levels
7.0% (27), consistent with data in the
generaldiabetespopulation.Foragiven
patient, the rise and fall in A1C may be
a useful indicator of trends in glycemic
control. Thus, regular monitoring of
A1C is advised.
A1C measurement is recommended
quarterly for patients with CFRD.
(ADA-E; Consensus)
For most patients with CFRD, the
A1C treatment goal is <7% to
reduce the risk of microvascular
complications, bearing in mind that
higher or lower goals may be
indicated for some patients and that
individualization is important.
(ADA-B; USPSTF-B)
Diet and exercise in CFRD
CF patients have nutrition requirements
which are well established (62–64). Be-
cause adequate caloric intake to maintain
BMIiscriticaltotheirhealthandsurvival,
theadditionaldiagnosisofCFRDdoesnot
alter usual CF dietary recommendations
(Table3).Thegoalistoachieveandmain-
taingoodnutritionalstatusandnormalize
blood glucose levels.
CF patients require a very high-
calorie diet that is usually 120–150% of
the daily recommended intake for age be-
causetheyhavebothincreasedrestingen-
ergy expenditure and increased loss of
calories through malabsorption. Thus,
caloriesshouldalmostneverberestricted.
Theneedforhighcaloricintake,however,
does not replace well-established princi-
plesofgoodnutritionandahealthy,well-
balanceddiet.ABMI50thpercentilefor
ages 2–20 years and for adults a BMI 22
kg/m
2forfemalesubjectsand23kg/m
2
formalesubjectsisthegoalforallpersons
with CF (64). The use of carbohydrate
counting and insulin-to-carbohydrate ra-
tios in conjunction with the usual CF diet
to guide insulin therapy can help to opti-
mize glycemic control.
CFF evidence–based guidelines for
nutritional management are
recommended for patients with
CFRD. (ADA-E; Consensus)
Exerciseisbeneﬁcialandisknowntoplay
a vital role in overall health. Most CF pa-
tients including those with severe pulmo-
nary disease (40% predicted FEV1) are
capable of engaging in strength and aero-
bic exercise activities (65).
Table 3—Dietary recommendations for CFRD
Nutrient Type 1 and type 2 diabetes CFRD
Calories As needed for growth, maintenance, or reduction diets 1.2–1.5 times DRI for age; individualized based
on weight gain and growth
Carbohydrate Individualized. Monitor carbohydrates to achieve
glycemic control; choose from fruits, vegetables,
whole grains and ﬁber-containing foods, legumes,
and low-fat milk. Sugar alcohols and nonnutritive
sweeteners are safe within U.S. Food and Drug
Administration–established consumption guidelines.
Individualized. Carbohydrates should be
monitored to achieve glycemic control.
Artiﬁcial sweeteners should be used sparingly
due to lower calorie content.
Fat Limit saturated fat to 7% of total calories; intake of
trans fat should be minimized; limit dietary
cholesterol to 200 mg/day. Consume two or more
servings per week of ﬁsh high in n-3
polyunsaturated fatty acids.
No restriction on type of fat. High fat necessary
for weight maintenance. Aim for 35–40%
total calories.
Protein 15–20% of total calories; reduction to 0.8–1.0 g/kg
with nephropathy
Approximately 1.5–2.0 times the DRI for age;
no reduction for nephropathy
Sodium 2,300 mg/day for blood pressure control Liberal, high salt diet, especially in warm
conditions and/or when exercising
Vitamins, minerals No supplementation necessary unless deﬁciency noted Routine supplementation with CF-speciﬁc
multivitamins or a multivitamin and
additional fat-soluble vitamins A, D, E, and K
Alcohol If consumed, limit to a moderate amount; one drink
per day for women and two or less drinks per day
for men.
Consult with physician because of the higher
prevalence of liver disease in CF and possible
use of hepatotoxic drugs.
Special circumstances
Gestational diabetes
mellitus
Restricted calories/carbohydrate for weight and blood
glucose control
No calorie or carbohydrate restriction;
adequate kcals for weight gain
IGT Weight loss of 5–10% recommended; low-fat diet No weight loss. Spread carbohydrates
throughout the day; consume nutrient-dense
beverages.
DRI, daily recommended intake.
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advised to do moderate aerobic
exercise for at least 150 min per
week. (ADA-E; Consensus)
COMPLICATIONS
Acute complications of CFRD
Acute complications of CFRD include
hypoglycemia and, rarely, diabetic keto-
acidosis (DKA) or hyperosmolar hyper-
glycemic state. Because DKA is so
uncommon (66), patients are not rou-
tinely taught to measure ketones and any
CF patient with DKA should be screened
for diabetes autoantibodies to rule out
type 1 diabetes.
Hypoglycemia that is not severe (i.e.,
not requiring assistance from another in-
dividual) is common even in CF patients
without CFRD. It occurs both in the fast-
ing state, where it may reﬂect malnutri-
tionand/orincreasedenergyneedsdueto
inﬂammation and infection, and post-
prandially, where it is related to delayed
and disordered insulin secretion (67). In-
sulin-induced hypoglycemia can occur in
CFRD as in any patient on insulin ther-
apy, although severe hypoglycemia may
be less common in CF (68). While CF
patients do not have a good glucagon re-
sponse to hypoglycemia (69), they have a
briskcatecholamineresponseandnormal
hypoglycemia awareness. Hypoglycemia
educationincludingtheuseofglucagonis
important for patients and their families.
Regular SMBG, especially during unusual
activity, diet changes, or illness is the best
protection against insulin-induced hypo-
glycemia (5). Patients should be coun-
seled regarding the hypoglycemic effects
of alcohol and the risks of driving or op-
erating machinery while hypoglycemic.
They should be encouraged to exercise;
however, they should be counseled to
check their glucose level before vigorous
physical activity and to potentially con-
sume extra carbohydrate or alter their in-
sulindose,dependingontheglucoselevel
and the intensity and duration of the
planned exercise.
Education about the symptoms,
prevention, and treatment of
hypoglycemia, including the use of
glucagon, is recommended for
patients with CFRD and their care
partners. (ADA-E; Consensus)
Chronic complications of CFRD
Microvascular disease does not typically
become clinically apparent in CFRD until
patients have had the disease for at least 5
years and have developed FH (27,41,70).
Tight glycemic control and treatment of
microalbuminuria with ACE inhibitors or
angiotensin receptor blockers combined
with optimal control of hypertension de-
layprogressionofdiabeticrenaldiseasein
the general diabetes population (5). They
areassumedtoalsobebeneﬁcialinCFRD
although there are no speciﬁc data in this
population. ACE inhibitors are associated
with development of cough in 10% of
subjects, and this can occur months after
drug initiation—a side effect with special
signiﬁcance in CF as increased cough is
among the symptoms of a pulmonary ex-
acerbation (71). Cough may also occur
with angiotensin receptor blockers but is
less frequent (1%).
Early diabetic nephropathy is charac-
terizedbymicroalbuminuria(aspoturine
ACR of 30–299 g/mg creatinine) (5).
Macroalbuminuria (300 g/mg creati-
nine) indicates clinically signiﬁcant ne-
phropathy that is progressing toward
renal failure. A patient must demonstrate
twooutofthreeabnormaltestswithina3-
to 6-month period to receive a diagnosis.
Renal failure due solely to diabetes is un-
common in CF, but microalbuminuria
has been reported to occur in 4–21% of
individuals with CFRD (27,41,70). Re-
cent strenuous exercise, fever, hyperten-
sion, congestive heart failure, infection,
menstruation,andorthostaticproteinuria
can result in a positive screen. It is there-
foreimportanttoexcludeothercausesbe-
fore concluding that microalbuminuria is
CFRD related.
Diabetic retinopathy is seen in 10–
23%ofpatientswithCFRDandisseldom
severe, although isolated severe cases
have been reported (27,41,43,70,72). As
in all persons with diabetes, dilated reti-
nal exams are necessary in patients with
CFRD to evaluate for the presence of ret-
inopathy and the need for treatment.
Annual neurologic assessment and
foot evaluation are recommended for the
general diabetes population (5). Current
data suggest that the severity of this mi-
crovascular complication may be less in
CFRD (27). Gastroparesis is common in
CF patients with and without CFRD, and
the role that CFRD plays in aggravating
this condition can be difﬁcult to deter-
mine (27). Gastroparesis may make good
glycemic control difﬁcult to achieve.
Hypertension is not uncommon in
adult CF patients, particularly after trans-
plantation (41). Although atherosclerotic
vasculardiseasehasnotbeendescribedin
CF, hypertension is a known risk factor
for diabetic kidney disease. As for all per-
sons with diabetes, the recommended
systolicanddiastolicbloodpressuregoals
are 130 mmHg and 80 mmHg, re-
spectively, or 90th percentile for age
and sex for pediatric patients (5). Hyper-
lipidemia is rare in CF but may occur,
especially after transplantation or in pan-
creatic-sufﬁcient individuals. While cho-
lesterol levels are typically quite low,
isolated triglyceride elevation has been
noted. Because CF patients are at low risk
foratheroscleroticcardiovasculardisease,
it is not clear that lipid elevation requires
treatment in this population, and there
arenodataregardingtheefﬁcacyorsafety
of medical therapy for CF dyslipidemia.
CFRD is not an autoimmune disease;
thus, there is no increased risk of other
autoimmune endocrinopathies.
Patients with CFRD should have their
blood pressure measured at every
routine diabetes visit as per ADA
guidelines. Patients found to have
systolic blood pressure >130 mmHg
or diastolic blood pressure >80
mmHg or >90th percentile for age
and sex for pediatric patients should
have repeat measurement on a sepa-
rate day to conﬁrm a diagnosis of hy-
pertension. (ADA-E; Consensus)
Annual monitoring for microvascular
complications of diabetes is recom-
mended using ADA guidelines, begin-
ning 5 years after the diagnosis of
CFRD or, if the exact time of diagno-
sis is not known, at the time that fast-
ing hyperglycemia is ﬁrst diagnosed.
(ADA-E; Consensus)
Patients with CFRD diagnosed with
hypertension or microvascular com-
plicationsshouldreceivetreatmentas
recommended by ADA for all people
with diabetes, except that there is no
restriction of sodium and, in general,
no protein restriction. (ADA-E;
Consensus)
An annual lipid proﬁle is recom-
mended for patients with CFRD and
pancreatic exocrine sufﬁciency or if
any of the following risk factors are
present: obesity, family history of
coronary artery disease, or immuno-
suppressive therapy following trans-
plantation. (ADA-E; Consensus)
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CONSIDERATIONS— The CFRD
Guidelines Committee identiﬁed the
following as the most pressing research
questions in CFRD: 1) Do nondiabetic
CF patients with abnormal glucose tol-
erance beneﬁt from diabetes therapy
and,ifso,whatmethodoftreatmenthas
the greatest impact on nutritional and
pulmonary status? 2) What are the ob-
stacles to OGTT screening of the CF
population and how can they best be
overcome? 3) What are the mechanisms
by which CFRD impacts pulmonary
function and survival in CF? 4) Should
target goals for glucose and/or A1C in
CFRD differ from ADA target goals? 5)
How can we assess and improve patient
acceptance of the diagnosis of CFRD to
improve diabetes self-management and
psychosocial well-being?
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